logo
Wrong email address or username
Wrong email address or username
Incorrect verification code
back to top
Search tags: medicine
Load new posts () and activity
Like Reblog Comment
text 2021-05-05 12:03
North American Nuclear Medicine Market To Reach USD 2.7 Billion By 2024 – Expansion In Emerging Economies

What This Report Will Provide?

The study involved four major activities in estimating the current size for the North American nuclear medicine market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

 

Expected Revenue Growth:

[159 Pages Report] The North American nuclear medicine market is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period.

 

Major Growth Boosters:

Growth in the market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer & cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices are expected to limit market growth to a certain extent.

 

Download PDF Brochure: Download PDF Brochure - North American Nuclear Medicine Market - Global Forecast to 2024 | MarketsandMarkets

 

Key Questions Addressed in The Report:

 

  • Which product segment will dominate the North American nuclear medicine market in the future?
  • Which application segment will dominate the market in the future?
  • Emerging countries offer immense opportunities for the growth and adoption of nuclear medicine; will this scenario continue in the coming five years?
  • Where will technology advancements offered by various companies take the industry in the mid- to long-term?
  • What are the upcoming products in the nuclear medicine market?

The alpha emitters segment is expected to command the largest share of the therapeutic nuclear medicine market in 2019

 

Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine. The therapeutic nuclear medicine segment is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes. In 2013, the FDA approved the first and only product for alpha emitters in the market, launched by Bayer AG under the name Xofigo (a Ra-223 dichloride molecule). The North American market for Ra-223 is expected to command the largest share owing to its targeted properties over beta emitters and being the only alpha-emitter product available in the market.

 

Request Sample Report: Sample Request - North American Nuclear Medicine Market - Global Forecast to 2024 | MarketsandMarkets

 

 

On the basis of type, which segment will command the largest market share?

 

On the basis of type, North America nuclear medicine market is segmented into diagnostic and therapeutic North America nuclear medicine. The diagnostic North America nuclear medicine market accounted for the largest share of the North America nuclear medicine market. The rising prevalence of cancer and cardiovascular diseases, increasing use of SPECT and PET imaging and advancements in radiotracers are driving the growth of this segment.

 

Regional Growth Analysis:

 

Geographically, the North American market comprises of US and Canada. In 2018, the US accounted for the largest share of the nuclear medicine market. The large share can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the country.

Source: www.marketsandmarkets.com/Market-Reports/north-american-nuclear-medicine-radiopharmaceuticals-market-1108.html
Like Reblog Comment
text 2021-05-03 06:11
Geriatric Medicine Market Will Rise Due To Growing Geriatric Population

Global Geriatric Medicine Market is expected to reach USD 1.01 Trillion By 2024. Geriatric medicine or geriatrics is a branch of medicine that focuses on medical issues and diseases of aging, and for old age. There is no specific age at which patients may undergo geriatric physician. The Geriatric Medicine Market is estimated to grow at a significant CAGR over the forecast period as the scope and its applications are rising enormously across the globe.

 

Growing geriatric population, increasing occurrence of several target diseases, and developed and affordable healthcare and medicines sector are documented as major factors of Geriatric Medicine Market that are estimated to enhance the growth in the years to come. However, difficulty in access to geriatric care among elderly patients in developing countries may restrain overall market growth in the coming years. Geriatric Medicine Market is segmented based on therapeutic, medical condition, and region.

 

Antidepressants, analgesics, antipsychotics, antihypertensive, anticoagulant, statins, proton pump inhibitor, and antidiabetics are the therapeutics that could be explored in Geriatric Medicine in the forecast period. Analgesics sector accounted for the significant market share of Geriatric Medicine and is estimated to lead the overall market in the coming years. In addition, antidiabetic sector is estimated to grow at fastest pace in the coming years.

 

For further inquiries, about - Global Geriatric Medicine Industry Analysis, Size, Growth, Trends and Forecast 2013 - 2024, click on this link – https://www.millioninsights.com/industry-reports/geriatric-medicine-market

 

Respiratory, cardiovascular diseases, osteoporosis, arthritis, cancer, and neurological Disorders are the therapeutic conditions that could be explored in Geriatric Medicine in the forecast period. Cardiovascular diseases sector accounted for the significant market share of Geriatric Medicine and is estimated to lead the overall market in the coming years.

 

Globally, North America accounted for the substantial market share of Geriatric Medicine and is estimated to lead the overall market in the coming years. The reason behind the overall market growth could be enhanced healthcare facilities & developed healthcare infrastructure, favorable reimbursement policy, rising number of old people suffering from several target diseases, and presence of key manufacturers in the region.

 

Instead, Europe and the Asia Pacific are also estimated to have a positive influence on the future growth. Europe is the second largest region with significant market share. However, Asia Pacific is estimated to grow at fastest pace with the highest CAGR in the foremost period. The aspects that may be ascribed to the growth comprise developing healthcare infrastructure, growth in disposable income, launch of many generic and patented drugs, and rise in private and public healthcare expenditure. The developing countries like India and China are the major consumers of Geriatric Medicine in the region.

 

The key players of Geriatric Medicine Market are Sanofi S.A., GlaxoSmithKline Plc, Merck & Company Inc., Boehringer Ingelheim GmbH, AstraZeneca plc, Novartis AG, Abbott Laboratories Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, and Pfizer, Inc. These players are concentrating on inorganic growth to sustain themselves amongst fierce competition. As companies all over the world have to believe that alliance with a market would permit them proportional market existence and authority to declare the leadership position.

 

Request a Free Sample Copy of Geriatric Medicine Market Report @ https://www.millioninsights.com/industry-reports/geriatric-medicine-market/request-sample

 

Market Segment:

 

Geriatric Medicine Market by therapeutic category (USD Billion, 2013 - 2024)
• Analgesics
• Antihypertensives
• Statins
• Antidiabetics
• Proton Pump Inhibitor
• Anticoagulant
• Antipsychotics
• Antidepressants

 

Geriatric Medicine Market by therapeutic condition, by Revenue (USD Billion,2013 - 2024)
• Cardiovascular diseases
• Arthritis
• Neurological Disorders
• Cancer
• Osteoporosis
• Respiratory

 

Geriatric Medicine Market Regional Outlook, by Revenue (USD Billion, 2013 - 2024)
• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• Asia Pacific
• Japan
• China
• Latin America
• Brazil
• Mexico
• MEA
• South Africa

 

To read more reports of this category, Visit our blog: https://healthandpharmamarketers.tumblr.com 

 

Like Reblog Comment
text 2021-03-03 11:24
North American Nuclear Medicine Market To Reach USD 2.7 Billion By 2024 – Expansion In Emerging Economies

What This Report Will Provide?

The study involved four major activities in estimating the current size for the North American nuclear medicine market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Expected Revenue Growth:

[159 Pages Report] The North American nuclear medicine market is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period

Major Growth Boosters:

Growth in the market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer & cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices are expected to limit market growth to a certain extent.

Download PDF Brochure: Download PDF Brochure - North American Nuclear Medicine Market - Global Forecast to 2024 | MarketsandMarkets

Key Questions Addressed in The Report:

  • Which product segment will dominate the North American nuclear medicine market in the future?
  • Which application segment will dominate the market in the future?
  • Emerging countries offer immense opportunities for the growth and adoption of nuclear medicine; will this scenario continue in the coming five years?
  • Where will technology advancements offered by various companies take the industry in the mid- to long-term?
  • What are the upcoming products in the nuclear medicine market?

The alpha emitters segment is expected to command the largest share of the therapeutic nuclear medicine market in 2019

Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine. The therapeutic nuclear medicine segment is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes. In 2013, the FDA approved the first and only product for alpha emitters in the market, launched by Bayer AG under the name Xofigo (a Ra-223 dichloride molecule). The North American market for Ra-223 is expected to command the largest share owing to its targeted properties over beta emitters and being the only alpha-emitter product available in the market.

Request Sample Report: Sample Request - North American Nuclear Medicine Market - Global Forecast to 2024 | MarketsandMarkets

On the basis of type, which segment will command the largest market share?On the basis of type, North America nuclear medicine market is segmented into diagnostic and therapeutic North America nuclear medicine. The diagnostic North America nuclear medicine market accounted for the largest share of the North America nuclear medicine market. The rising prevalence of cancer and cardiovascular diseases, increasing use of SPECT and PET imaging and advancements in radiotracers are driving the growth of this segment.

Regional Growth Analysis:

Geographically, the North American market comprises of US and Canada. In 2018, the US accounted for the largest share of the nuclear medicine market. The large share can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the country.

Source: www.marketsandmarkets.com/Market-Reports/north-american-nuclear-medicine-radiopharmaceuticals-market-1108.html
More posts
Your Dashboard view:
Need help?